The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodial
Comparison nafamostat and low molecular weight heparin among dialysis patients
| Condition(s) | Dialysis; Complications, Bleeding |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Comparison nafamostat and low molecular weight heparin among dialysis patients |
| Who can participate | Inclusion Criteria: * platelet below 10k PTT above 60 second INR above 20 patient with bleeding (epistaxis, orbital bleeding, hematuria) recent brain hemorrhage (within 6 months) receiving anticoagulant therapy (coumadin or NOAC) dual antiplatelet agent users received major surgery within one month Exclusion Criteria: * cancer liver cirrhosis pregnancy drug allergy current bleeding on major organ (brain, gastrointestinal) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Wonju Severance Christian Hospital |
| Locations | Wŏnju, Kangwondo, South Korea |
| Start date | 2023-12-01 |
| NCT ID | NCT05874674 |
| Official listing | https://clinicaltrials.gov/study/NCT05874674 |